FibroGen (NASDAQ:FGEN) Upgraded at HC Wainwright

HC Wainwright upgraded shares of FibroGen (NASDAQ:FGEN) to a strong-buy rating in a report issued on Tuesday,Zacks.com reports. HC Wainwright also issued estimates for FibroGen’s Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.74) EPS, FY2025 earnings at ($0.53) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.44) EPS.

FGEN has been the subject of a number of other research reports. StockNews.com initiated coverage on shares of FibroGen in a research report on Monday. They set a “hold” rating for the company. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Stock Performance

NASDAQ:FGEN opened at $0.35 on Tuesday. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.93. The stock has a fifty day moving average of $0.35 and a 200 day moving average of $0.57. The firm has a market capitalization of $35.64 million, a price-to-earnings ratio of -0.29 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The business had revenue of $46.33 million for the quarter, compared to the consensus estimate of $34.00 million. During the same quarter last year, the firm posted ($0.52) EPS. Equities analysts forecast that FibroGen will post -0.86 earnings per share for the current fiscal year.

Institutional Trading of FibroGen

Several large investors have recently bought and sold shares of the business. Point72 DIFC Ltd lifted its stake in FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 45,990 shares in the last quarter. Doheny Asset Management CA purchased a new position in shares of FibroGen in the 2nd quarter valued at about $48,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in FibroGen during the second quarter worth approximately $130,000. Sei Investments Co. raised its stake in FibroGen by 38.4% during the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 41,442 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of FibroGen in the 2nd quarter valued at about $145,000. Hedge funds and other institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.